Hepatic	hepatic	O	O
reactions	reactions	O	O
associated	associated	O	B_disease
with	with	O	I_disease
ketoconazole	ketoconazole	S_chemical	O
in	in	O	O
the	the	O	O
United	united	O	O
Kingdom	kingdom	O	O
.	.	O	O

Ketoconazole	ketoconazole	S_chemical	O
was	was	O	O
introduced	introduced	O	O
in	in	O	O
the	the	O	O
United	united	O	O
Kingdom	kingdom	O	O
in	in	O	O
1981	1981	O	O
.	.	O	O

By	by	O	O
November	november	O	O
1984	1984	O	O
the	the	O	O
Committee	committee	O	O
on	on	O	O
Safety	safety	O	O
of	of	O	O
Medicines	medicines	O	O
had	had	O	O
received	received	O	O
82	82	O	O
reports	reports	O	O
of	of	O	O
possible	possible	O	O
hepatotoxicity	hepatotoxicity	O	S_disease
associated	associated	O	B_disease
with	with	O	I_disease
the	the	O	O
drug	drug	O	O
,	,	O	O
including	including	O	O
five	five	O	O
deaths	deaths	O	S_disease
.	.	O	O

An	an	O	O
analysis	analysis	O	O
of	of	O	O
the	the	O	O
75	75	O	O
cases	cases	O	O
that	that	O	O
had	had	O	O
been	been	O	O
adequately	adequately	O	O
followed	followed	O	O
up	up	O	O
suggested	suggested	O	O
that	that	O	O
16	16	O	O
,	,	O	O
including	including	O	O
three	three	O	O
deaths	deaths	O	S_disease
,	,	O	O
were	were	O	O
probably	probably	O	O
related	related	O	O
to	to	O	O
treatment	treatment	O	O
with	with	O	O
the	the	O	O
drug	drug	O	O
.	.	O	O

Of	of	O	O
the	the	O	O
remainder	remainder	O	O
,	,	O	O
48	48	O	O
were	were	O	O
possibly	possibly	O	O
related	related	O	O
to	to	O	O
treatment	treatment	O	O
,	,	O	O
five	five	O	O
were	were	O	O
unlikely	unlikely	O	O
to	to	O	O
be	be	O	O
so	so	O	O
,	,	O	O
and	and	O	O
six	six	O	O
were	were	O	O
unclassifiable	unclassifiable	O	O
.	.	O	O

The	the	O	O
mean	mean	O	O
age	age	O	O
of	of	O	O
patients	patients	O	O
in	in	O	O
the	the	O	O
16	16	O	O
probable	probable	O	O
cases	cases	O	O
was	was	O	O
57.9	57.9	O	O
,	,	O	O
with	with	O	O
hepatotoxicity	hepatotoxicity	O	S_disease
being	being	O	O
more	more	O	O
common	common	O	O
in	in	O	O
women	women	O	O
.	.	O	O

The	the	O	O
average	average	O	O
duration	duration	O	O
of	of	O	O
treatment	treatment	O	O
before	before	O	O
the	the	O	O
onset	onset	O	B_disease
of	of	O	I_disease
jaundice	jaundice	O	S_disease
was	was	O	O
61	61	O	O
days	days	O	O
.	.	O	O

None	none	O	O
of	of	O	O
these	these	O	O
well	well	O	O
validated	validated	O	O
cases	cases	O	O
occurred	occurred	O	O
within	within	O	O
the	the	O	O
first	first	O	O
10	10	O	O
days	days	O	O
after	after	O	O
treatment	treatment	O	O
.	.	O	O

The	the	O	O
results	results	O	O
of	of	O	O
serum	serum	O	O
liver	liver	O	O
function	function	O	O
tests	tests	O	O
suggested	suggested	O	O
hepatocellular	hepatocellular	O	B_disease
injury	injury	O	I_disease
in	in	O	O
10	10	O	O
(	(	O	O
63	63	O	O
%	%	O	O
)	)	O	O
;	;	O	O
the	the	O	O
rest	rest	O	O
showed	showed	O	O
a	a	O	O
mixed	mixed	O	O
pattern	pattern	O	O
.	.	O	O

In	in	O	O
contrast	contrast	O	O
,	,	O	O
the	the	O	O
results	results	O	O
of	of	O	O
histological	histological	O	O
examination	examination	O	O
of	of	O	O
the	the	O	O
liver	liver	O	O
often	often	O	O
showed	showed	O	O
evidence	evidence	O	O
of	of	O	O
cholestasis	cholestasis	O	S_disease
.	.	O	O

The	the	O	O
characteristics	characteristics	O	O
of	of	O	O
the	the	O	O
48	48	O	O
patients	patients	O	O
in	in	O	O
the	the	O	O
possible	possible	O	O
cases	cases	O	O
were	were	O	O
similar	similar	O	O
.	.	O	O

Allergic	allergic	O	B_disease
manifestations	manifestations	O	I_disease
such	such	O	O
as	as	O	O
rash	rash	O	S_disease
and	and	O	O
eosinophilia	eosinophilia	O	S_disease
were	were	O	O
rare	rare	O	O
.	.	O	O

Hepatitis	hepatitis	O	S_disease
was	was	O	O
usually	usually	O	O
reversible	reversible	O	O
when	when	O	O
treatment	treatment	O	O
was	was	O	O
stopped	stopped	O	O
,	,	O	O
with	with	O	O
the	the	O	O
results	results	O	O
of	of	O	O
liver	liver	O	O
function	function	O	O
tests	tests	O	O
returning	returning	O	O
to	to	O	O
normal	normal	O	O
after	after	O	O
an	an	O	O
average	average	O	O
of	of	O	O
3.1	3.1	O	O
months	months	O	O
.	.	O	O

In	in	O	O
two	two	O	O
of	of	O	O
the	the	O	O
three	three	O	O
deaths	deaths	O	S_disease
probably	probably	O	O
associated	associated	O	B_disease
with	with	O	I_disease
ketoconazole	ketoconazole	S_chemical	O
treatment	treatment	O	O
the	the	O	O
drug	drug	O	O
had	had	O	O
been	been	O	O
continued	continued	O	O
after	after	O	O
the	the	O	O
onset	onset	O	B_disease
of	of	O	I_disease
jaundice	jaundice	O	S_disease
and	and	O	O
other	other	O	O
symptoms	symptoms	O	O
of	of	O	O
hepatitis	hepatitis	O	S_disease
.	.	O	O

Clinical	clinical	O	O
and	and	O	O
biochemical	biochemical	O	O
monitoring	monitoring	O	O
at	at	O	O
regular	regular	O	O
intervals	intervals	O	O
for	for	O	O
evidence	evidence	O	O
of	of	O	O
hepatitis	hepatitis	O	S_disease
is	is	O	O
advised	advised	O	O
during	during	O	O
long	long	O	O
term	term	O	O
treatment	treatment	O	O
with	with	O	O
ketoconazole	ketoconazole	S_chemical	O
to	to	O	O
prevent	prevent	O	O
possible	possible	O	O
serious	serious	O	O
hepatic	hepatic	O	B_disease
injury	injury	O	I_disease
.	.	O	O

